• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    Neurocrine Biosciences Inc. (NBIX)

    55.90 Up 1.13(2.06%) Nov 25, 4:00PM EST
    ProfileGet Profile for:
    Neurocrine Biosciences Inc.
    12780 El Camino Real
    San Diego, CA 92130
    United States - Map
    Phone: 858-617-7600
    Fax: 858-617-7602
    Website: http://www.neurocrine.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:94

    Business Summary 

    Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage include elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, as well as Phase I study for tourette syndrome. Its research programs comprise VMAT2 for movement disorders, bipolar disorders, and schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men’s and women’s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions. The company also develops pharmaceutical products for tardive dyskinesia, and other neurological and endocrine-related diseases and disorders. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Investor Relations
    Search Yahoo! for:
    More on Neurocrine Biosciences Inc.

    Corporate Governance 
    Neurocrine Biosciences Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Kevin C. Gorman Ph.D., 57
    Chief Exec. Officer, Pres and Director
    Mr. Timothy P. Coughlin CPA, 48
    Chief Financial Officer
    Dr. Dimitri E. Grigoriadis Ph.D., 57
    Chief Research Officer
    Dr. Christopher F. O'Brien M.D., 58
    Chief Medical Officer
    Dr. Haig P. Bozigian Ph.D., 57
    Chief Devel. Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders